Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00461851
Status:
COMPLETED
Last Update Posted:
2017-12-14
First Post:
2007-04-16
Brief Title:
Trial of Gemcitabine Carboplatin and Sorafenib in Chemotherapy-naive Patients With AdvancedMetastatic Bladder Carcinoma
Sponsor:
Yale University
Organization:
Yale University
Study Overview
Official Title:
A Phase II Multicenter Trial of Gemcitabine Carboplatin and Sorafenib in Chemotherapy-naive Patients With AdvancedMetastatic Bladder Carcinoma
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II nonrandomized multicenter study designed to evaluate time to progression and response proportion of patients with advanced or metastatic transitional cell carcinoma of bladder receiving 6 cycles of gemcitabine carboplatin and sorafenib and then maintenance sorafenib
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None